Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market to reach US$ 1012.03 million by 2029 - A Report by Reports N Markets

 2021-12-03 04:20:21

With time the Alpha-1 Antitrypsin Deficiency (AATD) has come to be recognized as one of the most common hereditary disorders globally. AATD is an inherited condition that is generated by liver and is characterized as a low or unpredictable level of alpha-1 protein.

AAT is a protein that protects the lungs and liver from damage, it is a type of protein that belongs to the class protease inhibitor. It has been found that patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases (COPD), and emphysema diseases.

The disease is often undiagnosed, and augmentation therapy is the most specific therapy for its treatment. This includes various preparations derived from pooled human plasma. Some of the different augmentation therapeutic methods to treat AAT deficiency disease are - Aralast, Prolastin, Zamaira/Respreeza, and Glassia.

Such therapies aim to slow down and prevent serious lung damages and address associated complications. For instance - life-long treatment with augmentation therapy or other available treatments and in severe cases lung transplant are some of the available treatment options for the disease.

Patients with AATD require well-organized care, for which augmentation therapy is specifically preferred treatment option. And recent advancements in the diagnostic tools for genetic diseases have made revolutionary progression in the diagnosis and treatment of AATD.

The improved diagnostic techniques for genetic disorders, along with rising incidence and prevalence of respiratory diseases across the world are expected to boost the Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy market during the forecast period.

This detailed study gives subjective and quantitative investigation of Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy. The report has been made after detailed analysis of market income across locales and further across every one of the significant nations. The stock side investigation covers the significant market players and their local and worldwide presence and systems. The geological examination done underlines on every one of the significant nations across North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Important takeaways of the report:

  • With valuation at US$ 201.74 million in 2020, Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy is expected to get up to US$ 1012.03 million by 2029. The growth is projected at an estimated CAGR of 20.0% over the period of next ten years.
  • The U.S FDA following a clinical trial of the AAT augmentation therapy for AATD have had approved a weekly use of it. The trial proved that weekly infusions in AAT-deficient individuals could raise normal plasma and lung epithelial fluid levels of AAT.  
  • The AATD therapy is now used worldwide, and is the only pulmonary genetic disease with effective therapy for all affected individuals.
  • The leading companies operating in the global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market are Grifols, Takeda Pharmaceutical, Kamada Pharmaceuticals, GlaxoSmithKline Plc., AstraZeneca, Boehringer Ingelheim GmbH, Pfizer Inc., Shire, LFB Biotechnologies, Alnylam Pharmaceuticals, Arrow Head Pharmaceuticals, Vertex Pharmaceuticals, Mereo Biopharma, Dicerna Pharmaceuticals, Inhibrx, Teva Pharmaceutical Industries Ltd., and LFB Biomedicaments S.A., and other market participants.
Latest Press Releases